[go: up one dir, main page]

AU2001296001A1 - Process for producing b-form nateglinide crystal - Google Patents

Process for producing b-form nateglinide crystal

Info

Publication number
AU2001296001A1
AU2001296001A1 AU2001296001A AU9600101A AU2001296001A1 AU 2001296001 A1 AU2001296001 A1 AU 2001296001A1 AU 2001296001 A AU2001296001 A AU 2001296001A AU 9600101 A AU9600101 A AU 9600101A AU 2001296001 A1 AU2001296001 A1 AU 2001296001A1
Authority
AU
Australia
Prior art keywords
producing
nateglinide
type crystals
crystals
nateglinide crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296001A
Inventor
Makoto Maruo
Yukiko Matsuzawa
Kazuo Miyazaki
Shigehiro Nishina
Michito Sumikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of AU2001296001A1 publication Critical patent/AU2001296001A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for producing B-type crystals of nateglinide substantially free of H-type crystals is provided, which comprises drying solvated wet crystals of nateglinide at a low temperature until no solvent remains and making a crystal conversion thereof. According to this method, B-type crystals of nateglinide can be produced at an industrial scale without allowing other forms of the crystalline polymorphism to coexist.
AU2001296001A 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal Abandoned AU2001296001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-324375 2000-10-24
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Publications (1)

Publication Number Publication Date
AU2001296001A1 true AU2001296001A1 (en) 2002-05-06

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296001A Abandoned AU2001296001A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Country Status (18)

Country Link
US (2) US20030229249A1 (en)
EP (1) EP1334964B1 (en)
JP (1) JP4225057B2 (en)
KR (1) KR100810930B1 (en)
CN (1) CN100422143C (en)
AT (1) ATE370115T1 (en)
AU (1) AU2001296001A1 (en)
BR (1) BR0114846A (en)
CA (1) CA2426745C (en)
CY (1) CY1106839T1 (en)
DE (1) DE60130014T2 (en)
DK (1) DK1334964T3 (en)
ES (1) ES2288997T3 (en)
MX (1) MXPA03003575A (en)
PT (1) PT1334964E (en)
RU (1) RU2275354C2 (en)
TW (1) TWI293290B (en)
WO (1) WO2002034713A1 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521366A (en) * 2000-03-17 2005-07-29 Ajinomoto Kk Drugs for complications of diabetes and neuropathy, and utilisation thereof
PT1334963E (en) * 2000-10-18 2007-09-20 Ajinomoto Kk Process for producing nateglinide crystal
BR0114728B1 (en) * 2000-10-18 2014-01-14 Method for producing an acylphenylalanine
CN100352432C (en) * 2000-10-24 2007-12-05 味之素株式会社 Nateglinide-containing preparation
ATE429217T1 (en) * 2000-10-24 2009-05-15 Ajinomoto Kk HYDROPHILIC MEDICINAL PREPARATIONS CONTAINING NATEGLINIDE
WO2003087039A1 (en) * 2002-04-15 2003-10-23 Ajinomoto Co., Inc. Novel nateglinide crystal
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
AU2003253971A1 (en) * 2002-07-18 2004-02-09 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
ATE349418T1 (en) * 2003-11-26 2007-01-15 A M S A Anonima Materie Sint E METHOD FOR PRODUCING B-FORM NATEGLINIDINE
CN1950331A (en) * 2004-05-07 2007-04-18 特瓦制药工业有限公司 Polymorphic forms of nateglinide
US20070231393A1 (en) * 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
US20080096970A1 (en) * 2004-05-20 2008-04-24 Sundaram Venkataraman Stable Nateglinide Form B Compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
WO2006080524A1 (en) * 2005-01-31 2006-08-03 Ajinomoto Co., Inc. Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (en) * 2006-12-26 2008-06-13 씨제이제일제당 (주) Nateglinide crystalline form, preparation method thereof, and pharmaceutical composition comprising the same
US9150499B2 (en) 2010-06-14 2015-10-06 Cipla Limited Process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
SG11201407303SA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
SG11201407314XA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
SG11201407319YA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (en) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
CN107108535B (en) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 Three-component salts of monomethyl fumarate with piperazine or ethylenediamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
CN104402756B (en) * 2014-11-27 2016-08-31 天方药业有限公司 A kind of preparation method of high-purity Nateglinide
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN109369443A (en) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 A kind of preparation method of new Nateglinide H crystal form

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (en) * 1985-03-27 1988-03-08 Ajinomoto Co Inc Blood sugar lowering agent
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
DE10199058I2 (en) * 1991-07-30 2006-04-27 Alcm Co Crystals of N- (trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine and process for their preparation
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
EP2277517A1 (en) * 1996-11-15 2011-01-26 Ajinomoto Co., Inc. Nateglinide tablet composition
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
CN1437483A (en) * 1999-12-28 2003-08-20 味之素株式会社 Oral preparations for diabetes
NZ521366A (en) * 2000-03-17 2005-07-29 Ajinomoto Kk Drugs for complications of diabetes and neuropathy, and utilisation thereof
PT1334963E (en) * 2000-10-18 2007-09-20 Ajinomoto Kk Process for producing nateglinide crystal
BR0114728B1 (en) * 2000-10-18 2014-01-14 Method for producing an acylphenylalanine
CN100352432C (en) * 2000-10-24 2007-12-05 味之素株式会社 Nateglinide-containing preparation
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
CY1106839T1 (en) 2012-05-23
MXPA03003575A (en) 2003-07-14
CN100422143C (en) 2008-10-01
US7544834B2 (en) 2009-06-09
EP1334964A4 (en) 2005-09-28
US20030229249A1 (en) 2003-12-11
DE60130014T2 (en) 2008-05-08
CA2426745A1 (en) 2003-04-23
RU2275354C2 (en) 2006-04-27
CA2426745C (en) 2009-09-15
KR20030059212A (en) 2003-07-07
EP1334964B1 (en) 2007-08-15
BR0114846A (en) 2004-02-25
US20070232829A1 (en) 2007-10-04
PT1334964E (en) 2007-09-20
KR100810930B1 (en) 2008-03-10
CN1483018A (en) 2004-03-17
JPWO2002034713A1 (en) 2004-03-04
WO2002034713A1 (en) 2002-05-02
EP1334964A1 (en) 2003-08-13
TWI293290B (en) 2008-02-11
DE60130014D1 (en) 2007-09-27
ES2288997T3 (en) 2008-02-01
ATE370115T1 (en) 2007-09-15
DK1334964T3 (en) 2007-09-24
JP4225057B2 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
AU2001296001A1 (en) Process for producing b-form nateglinide crystal
RU2003111948A (en) METHODS FOR OBTAINING NATEGLINIDE B-TYPE CRYSTALS
ATE396551T1 (en) METHOD FOR REDUCING POWER CONSUMPTION IN BLUETOOTH AND CDMA MODES
IL154122A0 (en) Crystalline and pure modafinil, and process of preparing the same
CA2248143A1 (en) Process to prepare oxazolidinones
PL357860A1 (en) Interketaled graphite compounds capable to expand, method of obtaining them and their applications
AU2001253376A1 (en) Improved process for the conversion of an aqueous biomass hydrolyzate into fuelsor chemicals by the selective removal of fermentation inhibitors
CA2279198A1 (en) Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
EP1318201A4 (en) Process for producing purified anthocyanin and crystalline anthocyanin
EP1348712A4 (en) L-nucleic acid derivatives and processes for the synthesis thereof
WO2003011228A3 (en) Purification and crystalline forms of zaleplon
BR0014993A (en) Process for the production of n-methyl pyrrolidone obtained by the reaction of gamma butyrolactone and mixed methylamines
CA2347853A1 (en) Process for racemization of [2-(2-thienyl)ethylamino] (2-halogenophenyl)acetamides
CA2326441A1 (en) Process for purification of a cephalosporin derivative
CA2234650A1 (en) Method for producing calcium borate
CA2490806A1 (en) Apparatus and method for use in solid phase chemical synthesis
DK1095009T3 (en) Process for the preparation of 4-carboxy-5,8,11-tris (carboxymethyl) -1-phenyl-2-oxa-5,8,11-triazatridecane-13-carboxylic acid
CA2358227A1 (en) Process for producing an amide compound
IL137119A0 (en) Process for preparing 2-acetylthio-3-phenyl-propionic acid and the salts thereof
EP1148046A4 (en) Process for the preparation of alpha-aminoketones
BR0209844A (en) Process for separation of crystalline imipenem
EP1431278A4 (en) METHOD OF PREPARING (2-NITROPHENYL) ACETONITRILE DERIVATIVES AND INTERMEDIATES THEREFOR
WO2003057665A1 (en) Process for producing crystal of benzenesulfonamide derivative, and novel crystal of intermediate therefor and process for producing the same
DE60023232D1 (en) Crystallization of alpha-L-aspartyl-L-phenylalanine methyl ester from supersaturated solutions
ATE423215T1 (en) METHOD FOR PRODUCING LYSOSPHINGOLIPIDS